Cytarabine is a pyrimidine nucleoside analogue antineoplastic agent used in the treatment of leukaemias and lymphomas.

<table>
<thead>
<tr>
<th>INN</th>
<th>Cytarabine</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATC codes</td>
<td>L01BC01</td>
</tr>
<tr>
<td>Medicine type</td>
<td>Chemical agent</td>
</tr>
</tbody>
</table>
| EML status history | First added in 1979 (TRS 641) for Lymphoid leukaemia, not elsewhere classified  
Added in 1979 (TRS 641) for Myeloid leukaemia  
Added in 1979 (TRS 641) for Burkitt lymphoma including Burkitt leukaemia  
Added in 1979 (TRS 641) for Acute myeloid leukaemia with recurrent genetic abnormalities  
Added in 1979 (TRS 641) for Unspecified malignant neoplasms of ill-defined or unspecified sites  
Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites |
| Wikipedia | Cytarabine |
| DrugBank  | Cytarabine |

**Recommendations**

**Section** Cytotoxic medicines

Parenteral > General injections > unspecified: 100 mg in vial powder for injection

**Indications**

- Lymphoid leukaemia, not elsewhere classified
- Myeloid leukaemia
- Acute myeloid leukaemia with recurrent genetic abnormalities
- Burkitt lymphoma including Burkitt leukaemia
- Unspecified malignant neoplasms of ill-defined or unspecified sites